To study the effect of eladi ointment

A Controlled Phase-II Clinical Study to evaluate efficacy of Eladi Ointment topically in Ekakushtha with special reference to Psoriasis

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/028022

Enrollment

Registered

2020-09-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Eladi ointment: 5 gm twice daily topically for 60 days Control Intervention1: Betnovate Ointment: 5 gm twice daily topically for 60 days

Eligibility

Inclusion criteria

Inclusion criteria: Patients with clinical features of Ekakushtha having signs and symptoms namely Kandu Shushkta Vaivarnya and Mastyashakloptam Irrespective of cast and socioeconomic status Understanding and being willing to sign the informed consent form The patients having the PASI score greater than equal to 10

Exclusion criteria

Exclusion criteria: Patient suffering from any chronic skin disease and immune suppressed systemic disorders Patient suffering from any other systemic disorders like tuberculosis diabetes melitus HIV HBsAg positive patients and known case of leprosy Pregnant and Lactating woman Psoriatic arthritis

Design outcomes

Primary

Measure	Time frame
Reduction scaly patches Reduction in area of scaly patchesTimepoint: 60 days	—

Secondary

Measure	Time frame
Reduction in ItchingTimepoint: 60 days	—

Countries

India

Contacts

Public ContactDr Sanjivani Nitin Rathod

Ayurved Seva Sangh Ayurved Mahavidyalaya Nashik

sanjivanirathod431@gmail.com8007229141

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026